FDA Misses Savara Deadline For Rare Lung Disease Drug
Savara said on November 20 that the FDA won't act on its molgramostim application by the November 22 target date, the agency gave no new date, and no approved treatment exists for the disease the drug targets.
Edited and fact-checked by Stephen Sprague
A missed date is a scheduling event, and the patients waiting on it keep the options they had.
Savara said on November 20 that the FDA won't act on its molgramostim application by the November 22 target date. The company learned the date would pass without a decision and announced the slip the same morning, two days before the deadline on the calendar, while the application stays under review. The agency gave Savara no revised date to put in its place.
Molgramostim is an inhaled form of GM-CSF, a protein signal that helps immune cells in the lungs clear material from the air sacs, and Savara delivers it through a nebulizer system built for the drug, because the nebulizer is an investigational eFlow system from PARI Pharma. The system was developed specifically for inhaling molgramostim, and autoimmune pulmonary alveolar proteinosis develops when surfactant builds up faster than those cells can remove it. Surfactant is the substance that keeps air sacs open, and breathing gets harder as the buildup grows.
"We appreciate the FDA's continued efforts on our application and look forward to working closely with the agency to complete its review," said Matt Pauls, Savara's chair and chief executive officer, and the statement is the whole of the company's public explanation. It names no dispute with the agency over safety, effectiveness or manufacturing, so a missed target date is a scheduling event. Readers shouldn't convert it into a verdict on the drug's evidence in either direction.
The review has already stretched once, because the FDA previously extended it by three months to assess additional information Savara submitted, and at the time of that extension the company said the regulator hadn't identified any safety, effectiveness or manufacturing concerns. That statement belongs to the earlier extension and not to the current delay, while the November 20 announcement offers no reason for the missed date at all.
No FDA-approved treatment exists for autoimmune PAP, and that gap is the practical weight behind a two-day slip in a review calendar, because available care includes whole-lung lavage. The procedure is performed under general anesthesia, and clinicians repeatedly wash out a patient's lungs to remove the accumulated material. A patient whose breathing is failing faces that procedure or continued decline while an inhaled alternative waits in a review queue.
Molgramostim's safety and effectiveness haven't been established, and the drug holds no approval from the FDA or any other regulatory authority, while Savara is a clinical-stage company based in Yardley, Pennsylvania. Molgramostim is its lead program, so the review carries the firm's whole near-term future, and investors marked the uncertainty before the market opened. Savara's shares fell 16% in premarket trading after the announcement.
The next verifiable milestone is a communication the company doesn't control, because the FDA will either act on the application or give Savara a new date to disclose, and until one of those arrives the record holds three facts in a row. A deadline existed, the agency said it would miss the deadline, and the patients the drug is meant for keep the treatment options they already had.
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.